Comment on CMS-2026-1255-0001

Summary: The National Multiple Sclerosis Society supports the proposed rule to modernize interoperability and prior authorization (PA) for drugs, particularly for chronic diseases like MS. They advocate for specific improvements including expedited timelines for MS-related requests, clearer denial reasons, and the inclusion of Medicare Part D plans in public reporting and timeframe requirements.